SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors,...

SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024 DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020 NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...